Research in gene therapy and other areas in recent years has led to many significant advances in efforts to develop new curative therapies for a range of serious diseases and conditions. Products including Kymriah, Yescarta, and Luxturna have been launched, and many others are advancing to late stage development. In this article published in Managed Healthcare Executive, Matthew Majewski considers new options for pricing models to keep pace with innovation in the development of high-cost gene, cell therapies.
To read the article, click here.
Approaching the final frontier: Are we in a golden decade of drug development for the central nervous system?
In this CRA Insights, the authors Will Foster, Kees Chamberlain, Joanne Clark, and Carl Lottig recount the recent scientific and technological advances in...